Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma
Stopped early · Early Phase 1
Conditions studied: Multiple Myeloma and Plasma Cell Neoplasm
In brief
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Interleukin-6 may stimulate the white blood cells to kill cancer cells. Giving interferon alfa together with interleukin-6 may kill more cancer cells. PURPOSE: This clinical trial is studying the side effects and how well giving interferon alfa together with interleukin-6 works in treating patients with recurrent multiple myeloma.
Key facts
- Study ID
- NCT00470093
- Run by
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- People needed
- 3
- Starts
- 2007-10-01
- Expected to finish
- 2010-01-01
- Last updated by the study team
- 2018-11-16
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.